Clinical Trial Update: AflacLL1901 (CHOA-AML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AflacLL1901 (CHOA-AML) in childhood acute myeloid leukemia; the study has been terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Childhood Acute Myeloid Leukemia

Drugs mentioned

• AflacLL1901 (CHOA-AML)

Snippet

Sponsor: Emory University | Conditions: Acute Myeloid Leukemia, AML, Childhood | Phase 2 | Status: TERMINATED | Results posted: 2022-06-15